Scarica l'app Stockscreener
0.4576
1.80%
-0.0084
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Nasdaq warns Jasper Therapeutics (JSPR) on sub-$1 bid, delisting risk noted - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate - Dailyhunt
JSPR Q1 2026 Earnings: Massive EPS Beat with -$0.04 vs -$0.4965 Estimate; Stock RisesEarnings Power Value - newsline.com
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long - Benzinga
Bears are losing control over Jasper Therapeutics (JSPR), here's why it's a 'buy' now - MSN
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - sharewise.com
Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value - marketscreener.com
Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives - Moomoo
Jasper Therapeutics Weighs Sale as Cash Dwindles, Drug's Fate Uncertain - BriefGlance
Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1 - Minichart
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty - TipRanks
Jasper Therapeutics explores strategic alternatives By Investing.com - Investing.com South Africa
Jasper Therapeutics explores strategic alternatives - Investing.com
Jasper Therapeutics begins strategic review to maximize shareholder value - TradingView
Jasper Therapeutics (NASDAQ: JSPR) weighs sale, merger or wind-down options - Stock Titan
Biotech Jasper Therapeutics weighs options from asset sale to wind-down - Stock Titan
JSPR Q1 2026 Earnings: Surprise EPS Beat Overshadowed by Broader HeadwindsAnnual Financial Report - The Legal Advocate
JSPR Q1 2026 Earnings: Narrowed Loss Surpasses Estimates, Stock Slides Despite ProgressProduct Revenue Analysis - newsline.com
Jasper Therapeutics (JSPR) Hovers Near Support as Biotech Sentiment Remains CautiousWave Equality - The Legal Advocate
Jasper Therapeutics (JSPR) Edges Higher: Small-Cap Biotech Tests Resistance at $0.95ETF Flow - The Legal Advocate
Jasper Therapeutics (JSPR) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock Higher - The Legal Advocate
Jasper Therapeutics Announces Board Resignation and Committee Change - TipRanks
Christian Nolet resigns from Jasper Therapeutics board; Svetlana Lucas joins Audit Committee - TradingView
Jasper Therapeutics (NASDAQ: JSPR) reports director exit and audit change - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionGeovax Labs (NASDAQ:GOVX), Jasper Therapeu - Benzinga
Jasper Therapeutics (JSPR) Q1 2026 Earnings: $-0.04 EPS Surges Past $-0.50 EstimatesSaaS Earnings Trends - The Legal Advocate
Jasper Therapeutics, Inc.Class A Common Stock (NQ: JSPR - The Chronicle-Journal
Jasper Therapeutics stock maintains outperform rating at Citizens By Investing.com - Investing.com Canada
JSPR Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Hold Rating, Cuts Target Price to $3 - Moomoo
JSPR Maintained by RBC Capital -- Price Target Lowered to $3.00 - GuruFocus
RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Moomoo
TD Cowen Downgrades Jasper Therapeutics(JSPR.US) to Hold Rating - Moomoo
TD Cowen downgrades Jasper Therapeutics stock rating to Hold By Investing.com - Investing.com Canada
Jasper Therapeutics, Inc. Stock 12‑Month Price Target Cut to $9.08, Implies 847% Upside - TradingView
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN
Jasper Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] Jasper Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Jasper drug sees 67% complete response in CSU trial update - Stock Titan
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Jasper Therapeutics (NASDAQ: JSPR) cuts Q1 2026 loss but flags funding risk - Stock Titan
Jasper Therapeutics (JSPR) price target decreased by 13.33% to 7.73 - MSN
Morgan Stanley units report sub‑5% stakes in Jasper Therapeutics (JSPR) - Stock Titan
TradingKey - TradingKey
The strategic priorities reflected in Jasper Therapeutics (JSPR) results | Q4 2025: Profit SurprisesRevenue Growth - Newser
1.04%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):